Background-The purpose of this study was to examine whether at-diagnosis smoking and postdiagnosis changes in smoking within five years after breast cancer were associated with longterm all-cause and breast cancer-specific mortality.
CI=0.79 to 3.23) among at-/postdiagnosis current smokers, but the confidence interval included the null value and elevated 175% (HR=2.75, 95% CI=1.26 to 5.99) when we considered postdiagnosis cumulative pack-years. Conclusions: Smoking negatively impacts long-term survival after breast cancer. Postdiagnosis cessation of smoking may reduce the risk of all-cause mortality. Breast cancer survivors may benefit from aggressive smoking cessation programs starting as early as the time of diagnosis.
Breast cancer is a serious public health problem in the United States, with more than 250 000 new breast cancer cases expected in 2017 (1) . Although there have been vast improvements in breast cancer treatment over the last few decades (2) and breast cancer survival rates are high, estimated at 90% at five years after diagnosis, approximately 40 000 women will die from breast cancer in 2017 (1) . This makes breast cancer the second leading cause of cancer-related death among women (1) . The high incidence of breast cancer together with the high rate of survival contribute to an estimated 3.1 million breast cancer survivors (3).
After breast cancer diagnosis, survivors may be motivated to make behavioral and lifestyle changes if they believe it will help improve prognosis, quality of life, and survival (4) . For the 10% to 20% of women who are smokers at the time of breast cancer diagnosis (5, 6) , smoking cessation is one important behavioral change that may improve survival after breast cancer. Cigarettes are known to contain more than 7000 chemicals, including 69 known carcinogens such as benzene, arsenic, formaldehyde, vinyl chloride, N-nitrosamines, and polycyclic aromatic hydrocarbons (PAHs) (7) . Therefore, it is not surprising that the association between smoking and breast cancer incidence has been extensively studied; at least 130 epidemiologic studies have examined this association, yet there is no scientific consensus (8) . In addition to differences in study design and exposure assessment, the conflicting results may in part be explained by both the carcinogenic and estrogenic effects of cigarette smoke constituents on breast epithelial cells (9, 10) and the anti-estrogenic effects of smoking on menstrual function (11, 12) . In their meta-analysis of more than 991100 women from 15 cohort studies, Gaudet and colleagues reported a 12% increase in breast cancer incidence, which was further elevated among women who initiated smoking before a first birth and among women who developed estrogen receptor-positive (ER+) tumors (8) . The few studies of smoking at the time of diagnosis and survival after breast cancer conducted to date consistently report a positive association between smoking and breast cancer-specific mortality (6, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . However, to date only one study (24) has prospectively considered the impact of post-diagnosis changes in smoking on survival.
This current study aimed to examine whether smoking at the time of diagnosis and changes in smoking within five years after diagnosis were associated with long-term all-cause and breast cancer mortality among a population-based sample of women diagnosed with first primary breast cancer.
Methods
We used resources from the Long Island Breast Cancer Study Project (LIBCSP), a population-based study of newly diagnosed breast cancer cases who were residents of Nassau and Suffolk counties on Long Island, New York, at the time of diagnosis. Details of the LIBCSP design have been published previously (25, 26) . Institutional review board approval was obtained from all participating institutions and in accordance with an assurance filed with and approved by the US Department of Health and Human Services.
Study Population
English-speaking women with a first primary diagnosis of in situ or invasive breast cancer were identified for inclusion using rapid-case ascertainment via active daily or weekly contact with local hospitals and confirmed by a physician and medical records. Additional eligibility criteria included being older than age 20years and a resident of Nassau or Suffolk county on Long Island, New York, at the time of diagnosis between August 1, 1996, and July 31, 1997. The study reported here includes the 1508 case women who were interviewed at baseline, on average within three months of diagnosis (mean = 3.19months). These women were primarily white (94%), with a mean age of 59years (range = 25-98 years), and postmenopausal (68%) at diagnosis (Table 1) .
Of the 1508 women who provided signed informed consent and completed the 100-minute, in-home, interviewer-administered, structured baseline questionnaire, 1414 agreed to continued contact. Approximately five years after the initial diagnosis of breast cancer, these 1414 women were recontacted for the follow-up interview. Informed consent was obtained by telephone from 1120 of the 1414 women (ie, 143 refused by mail or telephone, no proxy was identified for 96 women who were not alive at follow-up, and 55 could not be located). Of the 1120 consenting women, 65 were only able to provide limited information and 22 were refusals after consent and were therefore excluded. A 45-minute intervieweradministered, structured questionnaire that assessed information similar to that obtained at the time of diagnosis but regarding the time period since the initial diagnosis of breast cancer was completed by telephone by 1033 (68.5%) women, on average 5.48 years after diagnosis (range = 4.39-7.34years) (27) .
Smoking Assessment
Smoking history, including smoking status, intensity, and duration, was determined via interviewer-administered questionnaires at baseline and at five-year follow-up (28) . Smokers were defined as women who smoked at least one cigarette a day for six months or longer. Smoking status at baseline was defined as never, former, and current smoking in the year before diagnosis, and smoking status at the follow-up was similarly defined, but in the year before the follow-up interview. Intensity of smoking, or the number of cigarettes smoked per day, was categorized as fewer than 20 cigarettes per day and 20 or more cigarettes per day. Duration of smoking, or the total number of years of smoking excluding any time periods the women reported having not smoked, was categorized as less than 15 years, 15 to less than 30 years, and 30 or more years of smoking. Cigarette pack-years was calculated by multiplying the average number of cigarette packs smoked per day and the total number of years of smoking and was categorized as less than 15 pack-years, 15 to less than 30 packyears, and 30 or more pack-years. At baseline, smoking cessation (recency) among former smokers was categorized as less than five years, five to less than 10 years, and 10 or more years. In the analyses of postdiagnosis changes in smoking, each combination of at-diagnosis/postdiagnosis smoking was examined (ie, never/never smokers, former/former smokers, current/former smokers, and current/current smokers).
Covariate Assessment
Covariates were assessed by interviewer-administered questionnaire. Potential confounders were selected using directed acyclic graphs (29) and putative relationships based on previous studies of smoking and breast cancer survival. These covariates included age at diagnosis (years), total annual household income (<$15 000-$24999, $25 000-$49 999, and >$50 000), education (<high school or high school graduate, some college or college graduate, and postcollege), marital status (married or living as married vs not married, divorced, or widowed), body mass index (continuous, kg/m 2 ), at-diagnosis recreational physical activity (never, former, and current physical activity of least one hour per week for three months or more), and at-diagnosis intake of alcoholic beverages such as beer, wine, or liquor (never, former, and current intake at least once a month for six months or more).
Estrogen receptor status and nodal involvement were determined by medical record review, and tumor size was obtained from the New York State Cancer Registry. At baseline, women were interviewed after surgery but before initiation of most other components of the first course of treatment for the first primary breast cancer. Therefore, treatment received (radiation therapy, chemotherapy, or hormone therapy) was assessed by self-report at the follow-up questionnaire, which showed high agreement with medical record data (radiation therapy κ = 0.97, chemotherapy κ = 0.96, hormone therapy κ = 0.92) (30) but was more complete.
Outcome Assessment
We used the National Death Index (NDI) (31) to ascertain date of death and cause of death. Breast cancer-related deaths were identified using International Statistical Classification of Diseases 9 (174.9) and 10 (C-50.9) codes for deaths occurring before and after 1999, respectively, listed on the death certificate. Follow-up for mortality occurred from the date of diagnosis in 1996 to 1997 until December 31, 2014. The median duration of follow-up was 17.61years (range = 0.23-18.41 years). Among the 1508 women, 597 deaths occurred by the end of follow-up at 18+ years, 237 of which were breast cancer related.
Statistical Analysis
We used multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between at-diagnosis as well as at-/ postdiagnosis cigarette smoking and all-cause and breast cancer-specific mortality. The proportional hazards assumption was assessed by visual inspection of Kaplan-Meier curves and by testing exposure-by-time interactions in Cox models; no violations of the proportional hazards assumptions were observed. All analyses were done using the KaplanMeier and Cox Regression function in IBM SPSS Statistics version 22.0 (IBM Corp., Armonk, NY) and used never smokers as the referent group.
In the analyses of at-diagnosis smoking, survival time began at the date of breast cancer diagnosis and continued until the earlier of date of death or December 31, 2014. Age-adjusted and multivariable-adjusted models were fit for each of the exposures separately and for all-cause and breast cancer-specific mortality. The analyses of at-diagnosis smoking were not adjusted for disease and treatment characteristics, which occur and are ascertained after diagnosis and therefore do not meet the temporal condition necessary to be confounders. Furthermore, disease and treatment characteristics could be mediators if, for example, smoking influences the likelihood of estrogen receptor-positive breast cancer, which influences treatment and subsequent prognosis (8) .
The analyses of postdiagnosis change in smoking were restricted to the 1339 women who survived at least five years after diagnosis. Accordingly, survival time began at the date of completion of the follow-up questionnaire to the date of death or December 31, 2014, if alive. After excluding an additional seven women who reported being former smokers before diagnosis and current smokers at the follow-up questionnaire, the analytic sample consisted of 1332 women. Of these, 377 (28%) were lost to follow-up. Because a complete case analysis when data are not missing completely at random is inefficient and can potentially lead to biased results (32), we employed multiple imputation to account for the missing data. Missing values were imputed using SPSS, which employs a fully conditional specification (FCS) algorithm (33) . The FCS method is an iterative Markov Chain Monte Carlo procedure that sequentially imputes missing values for all covariates included starting from the first variable with missing values by specifying a linear regression or logistic regression model for each continuous or categorical variable, respectively. We used 25 imputations with 1000 iterations and included demographics (age at diagnosis, menopausal status, income, education, marital status, body mass index, physical activity, and alcohol intake), postdiagnosis smoking exposures (smoking status, number of cigarettes smoked per day at follow-up [minimum = 0], cumulative years of smoking [minimum = 0], and cumulative pack-years of smoking [minimum = 0]), disease characteristics (stage, tumor size, nodal status, estrogen receptor status), treatment (radiation therapy, chemotherapy, and hormone therapy), and the outcome (the event indicator and the Nelson-Aalen estimator of the cumulative hazard) (34) . The analyses of postdiagnosis smoking were additionally adjusted for stage, tumor size, nodal status, ER status, and chemotherapy treatment. In this report, we present the results from the full case analysis; however, the results of the complete case analysis for the age-adjusted estimates are available in the Supplementary Material (Supplementary Table 1 , available online).
Results

Prevalence of Smoking Among Women With Breast Cancer
Among the LIBCSP population-based sample of women diagnosed with first primary breast cancer in 1996 to 1997, 19% reported smoking within a year of their diagnosis About five years after diagnosis, 8% of women reported continued smoking and 11% reported that they had quit smoking since diagnosis.
At-Diagnosis Smoking and Survival After Breast Cancer
Compared with never smokers, current smoking at the time of breast cancer diagnosis was associated with a 69% increased hazard (HR = 1.69, 95% CI = 1.36 to 2.11) of all-cause mortality after covariate adjustment ( Table 2) . Risk of all-cause mortality was increased 50% for current smokers who smoked fewer than 20 cigarettes per day and 85% for current smokers who smoked 20 or more cigarettes per day (HR = 1.85, 95% CI = 1.42 to 2.40). Current smokers who had smoked for 15 to less than 30years had a 107% increased risk, and women who smoked 30 or more years had a 62% increased risk of all-cause mortality (HR = 1.62, 95% CI = 1.28 to 2.05). All-cause mortality was also increased among former smokers and current smokers who had smoked 30 or more pack-years (HR = 1.82, 95% CI = 1.39 to 2.37). Additionally, risk of all-cause mortality was elevated among former smokers who had quit smoking within five years of diagnosis, but not among women who had quit smoking five or more years before diagnosis. At-diagnosis smoking was not associated with breast cancer-specific mortality. Table 3 shows the results of the full case analyses utilizing the imputed data, and Supplementary Table 1 (available online) shows the results of the complete case analysis for the age-adjusted estimates. Overall, the results of both analyses are consistent. As shown in Table 3 , the risk of all-cause mortality was elevated 130% among women who continued smoking after diagnosis as compared with never smokers, after covariate adjustment (HR = 2.30, 95% CI = 1.56 to 3.39). However, risk of all-cause mortality was attenuated among women who quit smoking after diagnosis (HR = 1.83, 95% CI = 1.32 to 2.52). This pattern of association for women who quit smoking after diagnosis and women who continued smoking was consistent across high smoking intensity and high cumulative duration of smoking. However, women with 30 or more cumulative pack-years of smoking who quit after diagnosis had a slightly greater risk of mortality as compared with women who did not quit after diagnosis. These findings were similar among women with invasive breast cancer only (Supplementary Table 2 ) and stronger among women with ER+ breast cancer (Supplementary Table 3 ), though data were sparse.
At-/Postdiagnosis Smoking and Survival After Breast Cancer
At-/postdiagnosis smoking status, intensity, and duration were not statistically significantly associated with breast cancer-specific mortality. However, we noted elevations in the breast cancer-specific mortality rate among women who continued smoking after diagnosis (HR = 1.60, 95% CI = 0.79 to 3.23) and among women who continued smoking fewer than 20 cigarettes per day. Risk of breast cancer-specific mortality was elevated among women who continued smoking and who had smoked less than 30 cumulative pack-years (HR = 2.75, 95% CI = 1.26 to 5.99). Due to small numbers, we were unable to estimate the risk of mortality among women who continued smoking and who had smoked 30 or more cumulative pack-years.
Discussion
In this population-based study of women diagnosed with first primary breast cancer, atdiagnosis smoking was associated with a 69% increase in the risk of long-term all-cause, but not breast cancer-specific, mortality. Among women who continued smoking after breast cancer, the risk of all-cause mortality was elevated 130%. However, among the approximately 20% of women who quit smoking after diagnosis, the elevated mortality risk was attenuated. Additionally, among women who continued smoking, less than 30 cumulative pack-years of smoking was associated with more than a twofold increase in the risk of breast cancer-specific mortality.
While the carcinogenic constituents in tobacco smoke have been hypothesized to increase the risk of incident breast cancer (8), little is known about how these chemicals may increase risk of recurrence and subsequent mortality. PAHs, which are present in tobacco smoke, for example, can exert estrogenic as well as anti-estrogenic effects (35) and may be important in influencing survival in women with hormonally sensitive breast tumors. Our findings of an association between at-diagnosis smoking and all-cause, but not breast cancer-specific, mortality are inconsistent with most studies conducted to date, which report approximately a 30% increased risk (6); however, the confidence interval, which ranged from 0.77 to 1.51, suggests that these data may in fact be consistent. Among former smokers, we observed a suggestive inverse association with breast cancer mortality, which is consistent with at least two prior studies (36, 37) . One possible explanation for this finding is that successful quitters may also adopt healthier lifestyle behaviors, including an increase in the use of routine clinical preventive services such as mammographic screening (38) .
Studies examining smoking and mortality after breast cancer have primarily examined atdiagnosis smoking only (6) . However, one recently published study (24) prospectively evaluated changes in smoking status approximately six years after breast cancer diagnosis, which is an approach similar to that used in the study reported here. Although there were several differences in the study population in the study by Passarelli and colleagues, including the exclusion of women with in situ disease and women with stage IV disease in their study, Passarelli and colleagues reported similar estimates that were slightly larger in magnitude than those reported here for women who continued smoking after breast cancer for all-cause (HR=2.57, 95% CI =2.06 to 3.21, vs 2.30, 95% CI=1.56 to 3.39, respectively) and breast cancer-specific (HR=1.73, 95% CI =1.13 to 2.60, vs HR=1.60, 95% CI=0.79 to 3.23, respectively) mortality. These differences may arise from different approaches in addressing missing data. The response rate for the completion of our follow-up assessment was approximately 70%, which is better than the 40% in the study by Passarelli et al., and we addressed the missing data due to potential biases that may arise from a complete case analysis only (32) .
Similar to prior studies of smoking and mortality among breast cancer survivors, our study has several limitations. First, our assessments of smoking relied on self-report; however, smoking history has been shown to be reliably recalled and self-reported (39) . Although women with newly diagnosed breast cancer may misreport their smoking status, our prevalence estimates for at-diagnosis (19%) (6) and postdiagnosis smoking (8%) are consistent with prior studies (5, 40) . Second, although our study shows that smoking may adversely impact survival, we can only hypothesize about the underlying biological mechanisms given the complex nature of tobacco smoke. It is possible that our findings are confounded by changes in other behaviors such as alcohol intake after diagnosis, which we were unable to consider in the same models due to insufficient power; however, most studies of alcohol intake and breast cancer mortality have been null (41) . We also lacked information on specific stage at diagnosis, an important determinant of survival, as well as the reasons women quit smoking after diagnosis, both of which could potentially confound the associations with post-diagnosis smoking reported here. Third, the low number of breast cancer-specific deaths, in particular for the analyses examining postdiagnosis changes in smoking, resulted in estimates that were imprecise and may be one reason for any discrepancies in our results with previous studies. Fourth, we did not consider causes of death other than breast cancer, and thus the results from breast cancer-specific analysis do not necessarily translate into the absolute risk of this outcome (42) . However, our approach does accurately estimate the relative hazard (rate) of breast cancer-specific death and thus addresses how death from breast cancer is associated with smoking (42, 43) . This is an etiologically relevant question given the potential of cigarette smoke chemicals to disrupt the endocrine system. Last, while our prospective study design allowed us to assess changes in smoking status several years after breast cancer, a proportion of women were lost to followup and thus did not complete the follow-up assessment; however, we addressed the missing data using multiple imputation, resulting in valid statistical inferences that properly reflect the uncertainty due to missing values (44) .
The results of our study show that smoking negatively impacts long-term survival after breast cancer. These findings support clinical opportunities for promoting smoking cessation programs targeted to women newly diagnosed with breast cancer and continued throughout the survivorship continuum in order to reduce the risk of mortality associated with continued smoking. Emphasis should also be placed on systematically assessing the impact of smoking history, smoking status, and postdiagnosis changes in smoking on outcomes in clinical trials, which often fail to account for this important exposure (45) .
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